Free Trial

Trevi Therapeutics (TRVI) Stock Price, News & Analysis

Trevi Therapeutics logo
$6.82 -0.02 (-0.22%)
As of 03:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Trevi Therapeutics Stock (NASDAQ:TRVI)

Key Stats

Today's Range
$6.81
$7.19
50-Day Range
$5.47
$7.06
52-Week Range
$2.36
$7.48
Volume
1.87 million shs
Average Volume
1.47 million shs
Market Capitalization
$800.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.88
Consensus Rating
Buy

Company Overview

Trevi Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

TRVI MarketRank™: 

Trevi Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 238th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Trevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.30, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Trevi Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Trevi Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.49) to ($0.51) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Trevi Therapeutics is -15.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Trevi Therapeutics is -15.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Trevi Therapeutics has a P/B Ratio of 5.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Trevi Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.16% of the float of Trevi Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Trevi Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Trevi Therapeutics has recently decreased by 97.98%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Trevi Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Trevi Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.16% of the float of Trevi Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Trevi Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Trevi Therapeutics has recently decreased by 97.98%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Trevi Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.
  • Search Interest

    Only 9 people have searched for TRVI on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    18.30% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Trevi Therapeutics' insider trading history.
Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRVI Stock News Headlines

TRVI Trevi Therapeutics, Inc. - Seeking Alpha
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

TRVI Stock Analysis - Frequently Asked Questions

Trevi Therapeutics' stock was trading at $4.12 at the start of the year. Since then, TRVI shares have increased by 70.5% and is now trading at $7.0250.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) released its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04.
Read the conference call transcript
.

Trevi Therapeutics (TRVI) raised $70 million in an IPO on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager.

Trevi Therapeutics' top institutional shareholders include Diversified Trust Co (0.02%) and Farther Finance Advisors LLC (0.01%). Insiders that own company stock include David P Meeker, Thomas Sciascia, Jennifer L Good, Farrell Simon and Lisa Delfini.
View institutional ownership trends
.

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include JPMorgan Chase & Co. (JPM), Predictive Oncology (POAI), Ford Motor (F), Tesla (TSLA), Meta Platforms (META), Abbott Laboratories (ABT) and Bank of America (BAC).

Company Calendar

Last Earnings
5/06/2025
Today
7/18/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TRVI
CIK
1563880
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$29.00
Low Price Target
$7.00
Potential Upside/Downside
+197.2%
Consensus Rating
Buy
Rating Score (0-4)
3.30
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.45)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$47.91 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-58.41%
Return on Assets
-52.52%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.38
Quick Ratio
15.38

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.30 per share
Price / Book
5.40

Miscellaneous

Outstanding Shares
117,290,000
Free Float
95,828,000
Market Cap
$823.96 million
Optionable
Optionable
Beta
0.46
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:TRVI) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners